Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Zoledronic Acid Does Not Add to Upfront Docetaxel Survival Benefit in Advanced Prostate Cancer

October 5th 2015

An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.

Changes in Prostate Cancer Presentation for Radiation Oncology Care

October 3rd 2015

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Dr. Ferrari on LBH589 and Bicalutamide in CRPC

October 2nd 2015

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC

September 30th 2015

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.

One Clinic's Multidisciplinary Approach Optimizes the Use of Radium-223

September 20th 2015

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

Dr. Sartor on Significance of Radium-223 for Community Oncologists

September 16th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

Radium-223 Poised to Move Beyond Prostate Cancer

August 27th 2015

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

Medivation Acquires BioMarin's PARP Inhibitor Talazoparib

August 25th 2015

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Dr. Renzulli on Expanded Access Program With Radium-223

August 24th 2015

Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Start Discussions About Palliative Care Upon Initial Metastatic Diagnosis

August 11th 2015

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer

August 10th 2015

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Dr. Shore on Lack of Reported Symptoms in Men With Prostate Cancer

August 10th 2015

Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.

New Diagnoses of Prostate Cancer Decline Nearly 30% Following USPSTF PSA Decision

August 6th 2015

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Study Says Urologists in Solo Practice May Overuse Gonadotropin Agonists

August 5th 2015

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men With Intermediate or High-Risk Prostate Cancer See Survival Benefit From Increased Radiation Therapy

August 4th 2015

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Novel Radium-223 Combinations on the Horizon in Bone-Metastatic CRPC

July 29th 2015

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Dr. Edith Mitchell on Cancer Disparities Among African American Patients

July 29th 2015

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Concurrent Statin Use in ADT Patients Reduced All Cause, Prostate Cancer-Specific Deaths

July 29th 2015

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Dr. O'Sullivan on Radium-223 With Enzalutamide and Abiraterone in mCRPC

July 28th 2015

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Improved Survival Data Seen With Abiraterone as COUGAR Trial Concludes

July 27th 2015

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

NEXT PAGE
PREVIOUS PAGE